Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - androgen


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5024
Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN

Julie N. Graff · Matthew R. Smith · Fred Saad · Boris Hadaschik · Hiroji Uemura · Ji Youl Lee · Paul Mainwaring · David Olmos · Stéphane Oudard · Anil Londhe · Amitabha Bhaumik · Oliver Brendan Rooney · Angela Lopez-Gitlitz · Eric J. Small ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.11510
Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.

Shabbir M.H. Alibhai · Henriette Breunis · Richard Gregg · Aaron Richard Hansen · Padraig Warde · Narhari Timilshina · George Tomlinson · Anthony M. Joshua · Neil E. Fleshner · Urban Emmenegger ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2020.38.6_SUPPL.TPS383
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).

Mary-Ellen Taplin · Martin E. Gleave · Christopher H. Evans · Eleni Efstathiou · Philip W. Kantoff · Ashley E. Ross · Neal D. Shore · Alberto Briganti · Boris Hadaschik · Axel Heidenreich · Oliver Brendan Rooney · Shaozhou Ken Tian · Lisa Wetherhold · Weichun Xu · Shinta Cheng · Sabine Brookman-May · Angela Lopez-Gitlitz · Adam S. Kibel ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS1106
A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

David B. Page · Isaac Kim · Brie Chun · William L. Redmond · Maritza Martel · Motomi Mori · Dottie Wadell · Nicole Moxon · Staci L. Mellinger · Walter J. Urba · Ayca Gucalp · Tiffany A. Traina ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5059
A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.

Pai-Chi Teng · Yu Jen Jan · Junhee Yoon · Pin-Jung Chen · Jie-Fu Chen · Nu Yao · Shirley Cheng · Amber Lozano · Michael R. Freeman · Sungyong You · Hsian-Rong Tseng · Edwin M. Posadas ·

Medicine
PDF

Therefore, we propose that in the liver, high levels of androgens modulate the circadian clock through inhibiting Ezh2 expression and lowering the H3K27me3 mark that causes irregular patterns of metabolic gene expression leading to disrupted liver metabolism and development of NAFLD.

MON-230 Androgen-Induced Disruption of the Biological Clock: The Link between PCOS and NAFLD [10.1210/JS.2019-MON-230]


4%) who received FGA (bicalutamide or flutamide) and ARATA (abiraterone acetate or enzalutamide), respectively, as the first-line agent after the failure of primary androgen deprivation therapy (ADT).

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer [10.1007/s10147-019-01412-2]


Direct co-culture of androgen receptor-dependent/independent cell lines (LNCaP, C4-2B, and PC3) led cancer cells to display functional and molecular features as observed in vivo.

Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment [10.1038/s41413-019-0049-8]


Phytotherapeutic treatment is also applied in androgenetic alopecia, which is a condition characterized by hair loss and affects individuals of both sexes, with a higher prevalence in men.

Efficacy of phytotherapy in the treatment of androgenetic alopecia [10.33448/rsd-v8i5.868]


Use of statins, in contrast to previous studies, did not result in a decrease in PSA concentrations whereas low dose finasteride therapy (1 mg) for male androgenetic alopecia was associated with a lower PSA level.

PD35-08 ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBASE TRIAL [10.1097/01.JU.0000556340.70570.d4]


Highly Related Keywords from androgen

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals